Asia Pacific Seasonal Influenza Vaccine Market: Cell Culture Technology Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity

2011-12-16
Published : Dec-2011

Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity

Summary

GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Description” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2017. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines.  The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.

Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 8.9% during the period 2010-2017 from $1,154.9m in 2010 to $2,095.9m by 2017. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies.

GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2010-2017. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.

GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.

Scope

– Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
– Market forecasts for the seasonal influenza vaccines from 2010 to 2017
– Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
– Key drivers and restraints that have created significant impact on the market.
– Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
– Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
– Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the seasonal influenza vaccine market.

Reasons to buy

– Build effective strategies to launch their pipeline products by identifying potential geographies.
– Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
– Develop key strategic initiatives by studying the key strategies of top competitors.
– Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
– Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 11
2 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Introduction 14
2.1 GBI Research Report Guidance 15
3 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Market Overview 16
3.1 Production Cycle for the Seasonal Influenza Vaccines 16
3.2 The Asia-Pacific Region Seasonal Influenza Vaccine Market 16
3.3 Revenue for the Seasonal Influenza Vaccine Market 17
3.4 Geographical Segmentation 19
4 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Geographical Landscape 20
4.1 Australia 20
4.1.1 Vaccination Pattern 20
4.1.2 Cost of Vaccine 25
4.1.3 Total Revenue 26
4.2 New Zealand 28
4.2.1 Vaccination Pattern 28
4.2.2 Cost of Vaccine 33
4.2.3 Total Revenue 34
4.2.4 Major Players by Market Share 36
4.3 Taiwan 37
4.3.1 Vaccination Pattern 37
4.3.2 Cost of Vaccine 41
4.3.3 Total Revenue 42
4.3.4 Major Players by Market Share 44
4.4 Philippines 45
4.4.1 Vaccination Pattern 45
4.4.2 Cost of Vaccine 49
4.4.3 Total Revenue 50
4.4.4 Major Players by Market Share 52
4.5 Malaysia 53
4.5.1 Vaccination Pattern 53
4.5.2 Cost of Vaccine 57
4.5.3 Total Revenue 58
4.5.4 Major Players by Market Share 60
4.6 Hong Kong 61
4.6.1 Vaccination Pattern 61
4.6.2 Cost of Vaccine 65
4.6.3 Total Revenue 66
4.6.4 Major Players by Market Share 68
4.7 Singapore 69
4.7.1 Vaccination Pattern 69
4.7.2 Cost of Vaccine 73
4.7.3 Total Revenue 74
4.7.4 Major Players by Market Share 76
4.8 Japan 77
4.8.1 Vaccination Pattern 77
4.8.2 Cost of Vaccine 81
4.8.3 Total Revenue 82
4.8.4 Major Players in the Market 83
4.9 China 84
4.9.1 Vaccination Pattern 84
4.9.2 Cost of Vaccine 88
4.9.3 Total Revenue 89
4.9.4 Major Players in the Market 91
4.10 India 92
4.10.1 Vaccination Pattern 92
4.10.2 Cost of Vaccine 96
4.10.3 Total Revenue 97
4.10.4 Major Players in the Market 99
5 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Drivers and Restraints 100
5.1 Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 100
5.1.1 Threat of Pandemic Influenza 100
5.1.2 Increasing Vaccination Coverage for Seasonal Influenza Vaccines 101
5.1.3 Emergence of Novel Production Technologies and Vaccines 104
5.1.4 Population Growth 105
5.1.5 Economic Reasons 105
5.2 Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 105
5.2.1 Entry Barriers in the Seasonal Influenza Vaccine Market 105
5.2.2 Variable Demand 106
5.2.3 Limited Production Capacity 106
5.3 Australia 106
5.3.1 Drivers 106
5.3.2 Restraints 106
5.4 New Zealand 107
5.4.1 Drivers 107
5.4.2 Restraints 107
5.5 Taiwan 107
5.5.1 Drivers 107
5.5.2 Restraints 107
5.6 Philippines 108
5.6.1 Drivers 108
5.6.2 Restraints 108
5.7 Malaysia 108
5.7.1 Drivers 108
5.7.2 Restraints 108
5.8 Hong Kong 109
5.8.1 Drivers 109
5.8.2 Restraints 109
5.9 Singapore 109
5.9.1 Drivers 109
5.9.2 Restraints 110
5.10 Japan 110
5.10.1 Drivers 110
5.10.2 Restraints 110
5.11 China 111
5.11.1 Drivers 111
5.11.2 Restraints 111
5.12 India 111
5.12.1 Drivers 111
5.12.2 Restraints 111
6 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Regulatory Landscape 112
6.1 Registration Process and Regulations in Australia 112
6.2 Registration Process and Regulations in New Zealand 114
6.3 Registration Process and Regulations in Taiwan 117
6.4 Registration Process and Regulations in the Philippines 118
6.5 Registration Process and Regulations in Malaysia 120
6.6 Registration Process and Regulations in Hong Kong 122
6.7 Registration Process and Regulations in Singapore 123
6.8 Registration Process and Regulations in Japan 124
6.9 Registration Process and Regulations in China 126
6.10 Registration Process and Regulations in India 128
7 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Pipeline Analysis 130
7.1 Seasonal Influenza Vaccines – Promising Vaccines under Clinical Development 130
7.2 Profiles for Promising Vaccines under Clinical Development 131
7.2.1 Optaflu 131
7.2.2 GSK2186877A 131
7.2.3 Intanza / Flu-ID 132
7.2.4 Fluad Pediatric 133
7.2.5 FluBlok 133
7.3 Research and Development Pipeline 134
8 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Competitive Landscape 138
8.1 Major Seasonal Influenza Vaccines Marketed in the APAC Region 138
8.1.1 Fluarix 138
8.1.2 Vaxigrip 138
8.1.3 Influvac 138
8.1.4 Fluvax 138
8.1.5 Agrippal 138
8.2 Key Areas Focused for R&D 139
8.3 Competitive Profiling 140
8.3.1 Sanofi Pasteur 140
8.3.2 GlaxoSmithKline Biologicals 140
8.3.3 Abbott Laboratories (Solvay Pharmaceuticals) 140
8.3.4 CSL Biotherapies 140
8.3.5 Novartis Vaccines 141
8.3.6 Crucell N.V. (Berna Biotech) 141
9 Seasonal Influenza Vaccine Market in Asia-Pacific Region – M&A Landscape 142
9.1 Overview 142
9.2 Major Merger and Acquisition Deals, 2007-2011 142
9.2.1 AstraZeneca Acquires Medimmune 143
9.2.2 Sanofi-Aventis (now Sanofi) Acquires Acambis 143
9.2.3 Mymetics Acquires Virosome Biologicals 143
9.2.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock 143
9.2.5 Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan 144
9.2.6 Abbott Laboratories Acquires Solvay Pharmaceuticals 144
9.2.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno 144
9.2.8 Johnson & Johnson Acquires Crucell 144
9.2.9 GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals 144
9.3 M&A Deals by Year of Completion, 2007-2011 145
9.4 M&A Deals by Geography 146
9.5 Major Licensing Agreements, 2007-2011 146
9.5.1 Crucell enters into License Agreement with Adimmune Corporation 146
9.5.2 MedImmune Enters into Licensing Agreement with Sanofi Pasteur 147
9.5.3 Vivalis enters into Licensing Agreement with GlaxoSmithKline 147
9.5.4 Vivalis enters into Licensing Agreement with Nobilon International 147
9.5.5 MedImmune enters into Licensing Agreement with GlaxoSmithKline 147
9.5.6 Hemispherx Biopharma Enters Into Licensing Agreement with BIKEN 147
9.5.7 MedImmune Enters Into Licensing Agreement with BIKEN 147
9.5.8 MedImmune Enters Into Licensing Agreement with Omninvest 148
9.5.9 OPKO Health Enters Into Licensing Agreement with Academia Sinica 148
9.5.10 AltraVax Enters Into Licensing Agreement with Maxygen 148
9.5.11 Protein Sciences Expands Its Licensing Agreement with UMN Pharma for FluBlok and PanBlok 148
9.5.12 NasVax Extends Its Research Agreement with Novartis 148
9.5.13 iBio Enters Into Licensing Agreement With G-Con 148
9.6 Licensing Deals by Year of Completion, 2007-2011 149
9.7 Licensing Deals by Geography 150
10 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Appendix 151
10.1 Market Definitions 151
10.2 Abbreviations 151
10.3 Research Methodology 152
10.3.1 Coverage 152
10.3.2 The Scope of the Study 152
10.3.3 Secondary Research 153
10.3.4 Primary Research 153
10.3.5 Expert Panel Validation 155
10.4 Contact Us 156
10.5 Disclaimer 156
10.6 Sources 156

1.1 List of Tables
Table 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue, ($m), 2010-2017 17
Table 2: Seasonal Influenza Vaccine Market, Australia, Population (‘000), 2010-2017 20
Table 3: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Contribution by Age Groups (%), 2010-2017 21
Table 4: Seasonal Influenza Vaccine Market, Australia, Overall Vaccination Coverage (‘000), 2010 – 2017 23
Table 5: Seasonal Influenza Vaccine Market, Australia, Vaccination Coverage Break-up by Age Groups (‘000), 2010-2017 23
Table 6: Seasonal Influenza Vaccine Market, Australia, Overall Number of Doses (‘000), 2010-2017 23
Table 7: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Age Groups, (‘000), 2010-2017 24
Table 8: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Purchase Sector, (‘000), 2010-2017 25
Table 9: Seasonal Influenza Vaccine Market, Australia, Cost of Vaccine,($), 2010-2017 25
Table 10: Seasonal Influenza Vaccine Market, Australia, Revenue, ($m), 2010-2017 26
Table 11: Seasonal Influenza Vaccine Market, Australia, Revenue Breakdown, ($m), 2010-2017 27
Table 12: Seasonal Influenza Vaccine Market, New Zealand, Population (‘000), 2010-2017 28
Table 13: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution (%), 2010-2017 29
Table 14: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution by Age Groups (%), 2010-2017 29
Table 15: Seasonal Influenza Vaccine Market, New Zealand, Overall Vaccination Coverage (‘000), 2010-2017 31
Table 16: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Coverage by Age Groups (‘000), 2010-2017 31
Table 17: Seasonal Influenza Vaccine Market, New Zealand, Overall Number of Doses (‘000), 2010-2017 31
Table 18: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Age Groups (‘000), 2010-2017 32
Table 19: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Sector Contribution (‘000), 2010-2017 33
Table 20: Seasonal Influenza Vaccine Market, New Zealand Cost of Vaccine, ($), 2010-2017 33
Table 21: Seasonal Influenza Vaccine Market, New Zealand, Revenue, ($m), 2010-2017 34
Table 22: Seasonal Influenza Vaccine Market, New Zealand, Revenue Breakdown, ($m), 2010-2017 35
Table 23: Seasonal Influenza Vaccine Market, Taiwan, Population (‘000), 2010-2017 37
Table 24: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Contribution by Age Groups (%), 2010-2017 38
Table 25: Seasonal Influenza Vaccine Market, Taiwan, Overall Vaccination Coverage (‘000), 2010-2017 39
Table 26: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Coverage by Age Groups (‘000), 2010-2017 39
Table 27: Seasonal Influenza Vaccine Market, Taiwan, Overall Number of Doses (‘000), 2010-2017 39
Table 28: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Age Groups (‘000), 2010-2017 40
Table 29: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Sector Contribution (‘000), 2010-2017 41
Table 30: Seasonal Influenza Vaccine Market, Taiwan, Cost of Vaccine, ($), 2010-2017 41
Table 31: Seasonal Influenza Vaccine Market, Taiwan, Revenue, ($m), 2010-2017 42
Table 32: Seasonal Influenza Vaccine Market, Taiwan, Revenue Breakdown, ($m),  2010-2017 43
Table 33: Seasonal Influenza Vaccine Market, Philippines, Population (‘000), 2010-2017 45
Table 34: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Contribution by Age Groups (%), 2010-2017 46
Table 35: Seasonal Influenza Vaccine Market, Philippines, Overall Vaccination Coverage (‘000), 2010-2017 47
Table 36: Seasonal Influenza Vaccine Market, Philippines, Vaccination Coverage by Age Groups (‘000), 2010-2017 47
Table 37: Seasonal Influenza Vaccine Market, Philippines, Overall Number of Doses (‘000), 2010-2017 47
Table 38: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Age Groups (‘000), 2010-2017 48
Table 39: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Sector Contribution (‘000), 2010-2017 49
Table 40: Seasonal Influenza Vaccine Market, Philippines, Cost of Vaccine, ($), 2010-2017 49
Table 41: Seasonal Influenza Vaccine Market, Philippines, Revenue, ($m), 2010-2017 50
Table 42: Seasonal Influenza Vaccine Market, Philippines, Revenue Breakdown, ($m), 2010-2017 51
Table 43: Seasonal Influenza Vaccine Market, Malaysia, Population (‘000), 2010-2017 53
Table 44: Seasonal Influenza Vaccine Market, Malaysia, Overall Vaccinated Population Contribution (%), 2010-2017 54
Table 45: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Contribution by Age Groups (%), 2010-2017 54
Table 46: Seasonal Influenza Vaccine Market, Malaysia, Overall Vaccination Coverage (‘000), 2010-2017 55
Table 47: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Coverage by Age Groups (‘000), 2010-2017 55
Table 48: Seasonal Influenza Vaccine Market, Malaysia, Overall Number of Doses (‘000), 2010-2017 55
Table 49: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Age Groups (‘000), 2010-2017 56
Table 50: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Sector Contribution (‘000), 2010-2017 57
Table 51: Seasonal Influenza Vaccine Market, Malaysia, Cost of Vaccine, ($), 2010-2017 57
Table 52: Seasonal Influenza Vaccine Market, Malaysia, Revenue, ($m), 2010-2017 58
Table 53: Seasonal Influenza Vaccine Market, Malaysia, Revenue Breakdown, ($m),  2010-2017 59
Table 54: Seasonal Influenza Vaccine Market, Hong Kong, Population (‘000), 2010-2017 61
Table 55: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Contribution by Age Groups (%), 2010-2017 62
Table 56: Seasonal Influenza Vaccine Market, Hong Kong, Overall Vaccination Coverage (‘000), 2010-2017 63
Table 57: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Coverage by Age Groups (‘000), 2010-2017 63
Table 58: Seasonal Influenza Vaccine Market, Hong Kong, Overall Number of Doses (‘000), 2010-2017 63
Table 59: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Age Groups (‘000), 2010-2017 64
Table 60: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Sector Contribution (‘000), 2010-2017 65
Table 61: Seasonal Influenza Vaccine Market, Hong Kong, Cost of Vaccine, ($), 2010-2017 65
Table 62: Seasonal Influenza Vaccine Market, Hong Kong, Revenue, ($m), 2010-2017 66
Table 63: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Breakdown, ($m), 2010-2017 67
Table 64: Seasonal Influenza Vaccine Market, Singapore, Population (‘000), 2010-2017 69
Table 65: Seasonal Influenza Vaccine Market, Singapore, Overall Vaccinated Population Contribution (%), 2010-2017 70
Table 66: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Contribution by Age Groups (%), 2010-2017 70
Table 67: Seasonal Influenza Vaccine Market, Singapore, Overall Vaccination Coverage (‘000), 2010-2017 71
Table 68: Seasonal Influenza Vaccine Market, Singapore, Vaccination Coverage by Age Groups (‘000), 2010-2017 71
Table 69: Seasonal Influenza Vaccine Market, Singapore, Overall Number of Doses (‘000), 2010-2017 71
Table 70: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Age Groups (‘000), 2010-2017 72
Table 71: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Sector Contribution (‘000), 2010-2017 73
Table 72: Seasonal Influenza Vaccine Market, Singapore, Cost of Vaccine, ($), 2010-2017 73
Table 73: Seasonal Influenza Vaccine Market, Singapore, Revenue, ($m), 2010-2017 74

Filed in: Pharmaceutical
Tags: 
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
 $4950

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

“The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......
 $

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

“Digital Pharmacy market to register a CAGR of 17.0%  during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated  to grow at the highest rate during the forecast period” On the basis  ofdrug type, t......
 $4950

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......
 $4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
 $4950

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

“Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......
 $4950

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......
 $4950

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

“Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......
 $4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
 $4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
 $4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy